Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Feasibility of subtotal esophagectomy with systematic lymphadenectomy in selected elderly patients with esophageal cancer; a propensity score matching analysis.

Kanda M, Koike M, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Nakayama G, Omae K, Kodera Y.

BMC Surg. 2019 Oct 15;19(1):143. doi: 10.1186/s12893-019-0617-2.

2.

Fraser extracellular matrix complex subunit 1 promotes liver metastasis of gastric cancer.

Umeda S, Kanda M, Miwa T, Tanaka H, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Nakayama G, Koike M, Kodera Y.

Int J Cancer. 2019 Oct 9. doi: 10.1002/ijc.32705. [Epub ahead of print]

PMID:
31597194
3.

Phase II study of capecitabine plus oxaliplatin (CapOX) as adjuvant chemotherapy for locally advanced rectal cancer (CORONA II).

Hattori N, Nakayama G, Uehara K, Aiba T, Ishigure K, Sakamoto E, Tojima Y, Kanda M, Kobayashi D, Tanaka C, Yamada S, Koike M, Fujiwara M, Nagino M, Kodera Y.

Int J Clin Oncol. 2019 Sep 21. doi: 10.1007/s10147-019-01546-3. [Epub ahead of print]

PMID:
31542847
4.

Comparison of non-invasive liver reserve and fibrosis models: Implications for surgery and prognosis for hepatocellular carcinoma.

Sonohara F, Yamada S, Tanaka N, Tashiro M, Sunagawa Y, Morimoto D, Tanaka H, Takami H, Hayashi M, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Hepatol Res. 2019 Jul 1. doi: 10.1111/hepr.13400. [Epub ahead of print]

PMID:
31260575
5.

Albumin-Bilirubin Score Predicts Tolerability to Adjuvant S-1 Monotherapy after Curative Gastrectomy.

Miwa T, Kanda M, Tanaka C, Kobayashi D, Hayashi M, Yamada S, Nakayama G, Koike M, Kodera Y.

J Gastric Cancer. 2019 Jun;19(2):183-192. doi: 10.5230/jgc.2019.19.e15. Epub 2019 Apr 22.

6.

[A Case of Laparoscopic Hepatectomy and Combined Resection of Lymph Nodes and Ureter for Liver Metastasis after Colorectal Cancer Surgery, with Local Lymph Node Recurrence and Bilateral Hydronephrosis].

Sato T, Sakai H, Goto Y, Kojima S, Nomura Y, Nakayama G, Hirakawa Y, Mikagi K, Kawahara R, Ishikawa H, Hisaka T, Yasunaga M, Tanaka H, Akagi Y, Okuda K.

Gan To Kagaku Ryoho. 2019 Apr;46(4):751-753. Japanese.

PMID:
31164524
7.

Novel implications of combined arterial resection for locally advanced pancreatic cancer in the era of newer chemo-regimens.

Sonohara F, Yamada S, Takami H, Hayashi M, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y.

Eur J Surg Oncol. 2019 Oct;45(10):1895-1900. doi: 10.1016/j.ejso.2019.05.019. Epub 2019 May 22.

PMID:
31147087
8.

Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer.

Kato Y, Yamada S, Tashiro M, Sonohara F, Takami H, Hayashi M, Kanda M, Kobayashi D, Tanaka C, Nakayama G, Koike M, Fujiwara M, Kodera Y.

HPB (Oxford). 2019 Sep;21(9):1211-1218. doi: 10.1016/j.hpb.2019.01.012. Epub 2019 Feb 14.

PMID:
30773450
9.

Acute iliac arterial thrombosis during laparoscopic abdominoperineal resection.

Sahara K, Ishibe A, Yabuno T, Kondo H, Nakayama G, Yasuda S, Nishida T, Watanabe J, Uranaka Y, Akiyama H, Sugita A, Endo I.

J Surg Case Rep. 2019 Feb 5;2019(2):rjz020. doi: 10.1093/jscr/rjz020. eCollection 2019 Feb.

10.

Perioperative and prognostic implication of albumin-bilirubin-TNM score in Child-Pugh class A hepatocellular carcinoma.

Sonohara F, Yamada S, Tanaka N, Suenaga M, Takami H, Hayashi M, Niwa Y, Sugimoto H, Hattori N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Ann Gastroenterol Surg. 2018 Sep 27;3(1):65-74. doi: 10.1002/ags3.12212. eCollection 2019 Jan.

11.

Homeobox C10 Influences on the Malignant Phenotype of Gastric Cancer Cell Lines and its Elevated Expression Positively Correlates with Recurrence and Poor Survival.

Miwa T, Kanda M, Umeda S, Tanaka H, Tanaka C, Kobayashi D, Suenaga M, Hayashi M, Yamada S, Nakayama G, Koike M, Kodera Y.

Ann Surg Oncol. 2019 May;26(5):1535-1543. doi: 10.1245/s10434-019-07166-5. Epub 2019 Jan 23.

PMID:
30673899
12.

Increased Expression of DNAJC12 is Associated with Aggressive Phenotype of Gastric Cancer.

Uno Y, Kanda M, Miwa T, Umeda S, Tanaka H, Tanaka C, Kobayashi D, Suenaga M, Hattori N, Hayashi M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Ann Surg Oncol. 2019 Mar;26(3):836-844. doi: 10.1245/s10434-018-07149-y. Epub 2019 Jan 7.

PMID:
30617870
13.

Identification of a serum-based miRNA signature for response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy.

Niwa Y, Yamada S, Sonohara F, Kurimoto K, Hayashi M, Tashiro M, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y.

J Transl Med. 2019 Jan 3;17(1):1. doi: 10.1186/s12967-018-1762-6.

14.

Transanal extended rectal surgery with lateral pelvic lymph node dissection.

Aiba T, Uehara K, Mukai T, Hattori N, Nakayama G, Nagino M.

Tech Coloproctol. 2018 Nov;22(11):893-894. doi: 10.1007/s10151-018-1891-1. Epub 2018 Nov 27. No abstract available.

PMID:
30483903
15.

Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: long-term results from the N-SOG 03 trial.

Tomida A, Uehara K, Hiramatsu K, Maeda A, Sakamoto E, Okada Y, Kurumiya Y, Nakayama G, Nakamura M, Aiba T, Nagino M; Of the Nagoya Surgical Oncology Group.

Int J Clin Oncol. 2019 Apr;24(4):403-410. doi: 10.1007/s10147-018-1372-6. Epub 2018 Nov 23.

PMID:
30471067
16.

Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification.

Morimoto D, Yamada S, Murotani K, Sonohara F, Takami H, Suenaga M, Hayashi M, Niwa Y, Tashiro M, Hattori N, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y.

Pancreas. 2018 Nov/Dec;47(10):1350-1356. doi: 10.1097/MPA.0000000000001186.

PMID:
30286011
17.

Copine 5 expression predicts prognosis following curative resection of esophageal squamous cell carcinoma.

Umeda S, Kanda M, Koike M, Tanaka H, Miwa T, Tanaka C, Kobayashi D, Suenaga M, Hayashi M, Yamada S, Nakayama G, Kodera Y.

Oncol Rep. 2018 Dec;40(6):3772-3780. doi: 10.3892/or.2018.6742. Epub 2018 Sep 27.

PMID:
30272363
18.

Expression of sushi domain containing two reflects the malignant potential of gastric cancer.

Umeda S, Kanda M, Miwa T, Tanaka H, Tanaka C, Kobayashi D, Suenaga M, Hattori N, Hayashi M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Cancer Med. 2018 Oct;7(10):5194-5204. doi: 10.1002/cam4.1793. Epub 2018 Sep 27.

19.

Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer.

Tashiro M, Yamada S, Sonohara F, Takami H, Suenaga M, Hayashi M, Niwa Y, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y.

Ann Surg Oncol. 2018 Oct;25(11):3365-3371. doi: 10.1245/s10434-018-6699-8. Epub 2018 Aug 10.

PMID:
30097739
20.

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study).

Nakayama G, Mitsuma A, Sunagawa Y, Ishigure K, Yokoyama H, Matsui T, Nakayama H, Nakata K, Ishiyama A, Asada T, Umeda S, Ezaka K, Hattori N, Takami H, Kobayashi D, Tanaka C, Kanda M, Yamada S, Koike M, Fujiwara M, Fujii T, Murotani K, Ando Y, Kodera Y.

Oncologist. 2018 Aug;23(8):919-927. doi: 10.1634/theoncologist.2017-0640. Epub 2018 Jul 26.

21.

Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms.

Yamada S, Fujii T, Hirakawa A, Takami H, Suenaga M, Hayashi M, Niwa Y, Hattori N, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Pancreas. 2018 Sep;47(8):974-979. doi: 10.1097/MPA.0000000000001110.

PMID:
30028445
22.

Impact of the Controlling Nutritional Status Score on the Prognosis After Curative Resection of Pancreatic Ductal Adenocarcinoma.

Kato Y, Yamada S, Suenaga M, Takami H, Niwa Y, Hayashi M, Iwata N, Kanda M, Tanaka C, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Pancreas. 2018 Aug;47(7):823-829. doi: 10.1097/MPA.0000000000001105.

PMID:
29975352
23.

Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.

Tanaka N, Yamada S, Sonohara F, Suenaga M, Hayashi M, Takami H, Niwa Y, Hattori N, Iwata N, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y.

Sci Rep. 2018 Jun 29;8(1):9846. doi: 10.1038/s41598-018-28253-9.

24.

Pattern-Specific Transcriptomics Identifies ASGR2 as a Predictor of Hematogenous Recurrence of Gastric Cancer.

Tanaka H, Kanda M, Miwa T, Tanaka C, Kobayashi D, Umeda S, Shibata M, Suenaga M, Hattori N, Hayashi M, Iwata N, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Mol Cancer Res. 2018 Sep;16(9):1420-1429. doi: 10.1158/1541-7786.MCR-17-0467. Epub 2018 May 21.

25.

A novel dual-marker expression panel for easy and accurate risk stratification of patients with gastric cancer.

Kanda M, Murotani K, Tanaka H, Miwa T, Umeda S, Tanaka C, Kobayashi D, Hayashi M, Hattori N, Suenaga M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Cancer Med. 2018 Jun;7(6):2463-2471. doi: 10.1002/cam4.1522. Epub 2018 May 7.

26.

Integrated multigene expression panel to prognosticate patients with gastric cancer.

Kanda M, Murotani K, Tanaka H, Miwa T, Umeda S, Tanaka C, Kobayashi D, Hayashi M, Hattori N, Suenaga M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Oncotarget. 2018 Apr 10;9(27):18775-18785. doi: 10.18632/oncotarget.24661. eCollection 2018 Apr 10.

27.

Troponin I2 as a Specific Biomarker for Prediction of Peritoneal Metastasis in Gastric Cancer.

Sawaki K, Kanda M, Miwa T, Umeda S, Tanaka H, Tanaka C, Kobayashi D, Suenaga M, Hattori N, Hayashi M, Yamada S, Nakayama G, Fujiwara M, Kodera Y.

Ann Surg Oncol. 2018 Jul;25(7):2083-2090. doi: 10.1245/s10434-018-6480-z. Epub 2018 Apr 16.

PMID:
29663169
28.

Significance of Lysyl oxidase‑like 2 gene expression on the epithelial‑mesenchymal status of hepatocellular carcinoma.

Ninomiya G, Yamada S, Hayashi M, Takeda S, Suenaga M, Takami H, Kanda M, Iwata N, Niwa Y, Tanaka C, Kobayashi D, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Oncol Rep. 2018 Jun;39(6):2664-2672. doi: 10.3892/or.2018.6349. Epub 2018 Apr 2.

PMID:
29620290
29.

A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.

Oki E, Kato T, Bando H, Yoshino T, Muro K, Taniguchi H, Kagawa Y, Yamazaki K, Yamaguchi T, Tsuji A, Iwamoto S, Nakayama G, Emi Y, Touyama T, Nakamura M, Kotaka M, Sakisaka H, Yamanaka T, Kanazawa A.

Clin Colorectal Cancer. 2018 Jun;17(2):147-155. doi: 10.1016/j.clcc.2018.01.011. Epub 2018 Feb 9.

30.

Postoperative adalimumab maintenance therapy for Japanese patients with Crohn's disease: a single-center, single-arm phase II trial (CCOG-1107 study).

Asada T, Nakayama G, Tanaka C, Kobayashi D, Ezaka K, Hattori N, Kanda M, Yamada S, Koike M, Kodera Y.

Surg Today. 2018 Jun;48(6):609-617. doi: 10.1007/s00595-018-1634-y. Epub 2018 Feb 23.

PMID:
29476258
31.

PAX5 gene as a novel methylation marker that predicts both clinical outcome and cisplatin sensitivity in esophageal squamous cell carcinoma.

Kurimoto K, Hayashi M, Guerrero-Preston R, Koike M, Kanda M, Hirabayashi S, Tanabe H, Takano N, Iwata N, Niwa Y, Takami H, Kobayashi D, Tanaka C, Yamada S, Nakayama G, Sugimoto H, Fujii T, Fujiwara M, Kodera Y.

Epigenetics. 2017;12(10):865-874. doi: 10.1080/15592294.2017.1365207. Epub 2017 Nov 27.

32.

Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society.

Yamada S, Fujii T, Takami H, Hayashi M, Iwata N, Kanda M, Tanaka C, Sugimoto H, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Surgery. 2017 Oct;162(4):784-791. doi: 10.1016/j.surg.2017.04.023. Epub 2017 Jun 24.

PMID:
28655416
33.

The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902).

Nakayama G, Ishigure K, Yokoyama H, Uehara K, Kojima H, Ishiyama A, Hayashi N, Takano N, Hattori N, Kobayashi D, Tanaka C, Hayashi M, Kanda M, Yamada S, Sugimoto H, Koike M, Fujiwara M, Fujii T, Murotani K, Ando Y, Kodera Y.

BMC Cancer. 2017 Apr 4;17(1):243. doi: 10.1186/s12885-017-3245-1.

34.

GPR155 Serves as a Predictive Biomarker for Hematogenous Metastasis in Patients with Gastric Cancer.

Shimizu D, Kanda M, Tanaka H, Kobayashi D, Tanaka C, Hayashi M, Iwata N, Niwa Y, Takami H, Yamada S, Fujii T, Nakayama G, Fujiwara M, Kodera Y.

Sci Rep. 2017 Feb 6;7:42089. doi: 10.1038/srep42089.

35.

The Charlson age comorbidity index predicts prognosis in patients with resected pancreatic cancer.

Asano T, Yamada S, Fujii T, Yabusaki N, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Int J Surg. 2017 Mar;39:169-175. doi: 10.1016/j.ijsu.2017.01.115. Epub 2017 Feb 2.

36.

Stapling an extracorporeal Billroth-I anastomosis by the complete double stapling technique after laparoscopy-assisted distal gastrectomy.

Tanaka C, Fujiwara M, Kanda M, Murotani K, Iwata N, Hayashi M, Kobayashi D, Yamada S, Nakayama G, Sugimoto H, Koike M, Fujii T, Kodera Y.

Asian J Endosc Surg. 2017 May;10(2):137-142. doi: 10.1111/ases.12357. Epub 2017 Jan 27.

PMID:
28127939
37.

Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study.

Ninomiya G, Fujii T, Yamada S, Yabusaki N, Suzuki K, Iwata N, Kanda M, Hayashi M, Tanaka C, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Int J Surg. 2017 Mar;39:45-51. doi: 10.1016/j.ijsu.2017.01.075. Epub 2017 Jan 18.

38.

Prognostic relevance of SAMSN1 expression in gastric cancer.

Kanda M, Shimizu D, Sueoka S, Nomoto S, Oya H, Takami H, Ezaka K, Hashimoto R, Tanaka Y, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Oncol Lett. 2016 Dec;12(6):4708-4716. doi: 10.3892/ol.2016.5233. Epub 2016 Oct 6.

39.

The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy.

Shimizu D, Kanda M, Sugimoto H, Shibata M, Tanaka H, Takami H, Iwata N, Hayashi M, Tanaka C, Kobayashi D, Yamada S, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y.

Int J Oncol. 2017 Feb;50(2):381-386. doi: 10.3892/ijo.2017.3833. Epub 2017 Jan 2.

40.
41.

Modified two-dimensional response as surrogate marker of overall survival in patients with metastatic colorectal cancer.

Nakayama G, Fujii T, Murotani K, Uehara K, Hattori N, Hayashi M, Tanaka C, Kobayashi D, Kanda M, Yamada S, Sugimoto H, Koike M, Fujiwara M, Ando Y, Kodera Y.

Cancer Sci. 2016 Oct;107(10):1492-1498. doi: 10.1111/cas.13023.

42.

FAM46C Serves as a Predictor of Hepatic Recurrence in Patients with Resectable Gastric Cancer.

Tanaka H, Kanda M, Shimizu D, Tanaka C, Kobayashi D, Hayashi M, Iwata N, Yamada S, Fujii T, Nakayama G, Sugimoto H, Fujiwara M, Niwa Y, Kodera Y.

Ann Surg Oncol. 2017 Oct;24(11):3438-3445. doi: 10.1245/s10434-016-5636-y. Epub 2016 Oct 21.

PMID:
27770343
43.

Usefulness of preoperative estimated glomerular filtration rate to predict complications after curative gastrectomy in patients with clinical T2-4 gastric cancer.

Tanaka Y, Kanda M, Tanaka C, Kobayashi D, Mizuno A, Iwata N, Hayashi M, Niwa Y, Takami H, Yamada S, Fujii T, Nakayama G, Sugimoto H, Fujiwara M, Kodera Y.

Gastric Cancer. 2017 Jul;20(4):736-743. doi: 10.1007/s10120-016-0657-6. Epub 2016 Oct 12.

PMID:
27734274
44.

Epigenetic suppression of the immunoregulator MZB1 is associated with the malignant phenotype of gastric cancer.

Kanda M, Tanaka C, Kobayashi D, Tanaka H, Shimizu D, Shibata M, Takami H, Hayashi M, Iwata N, Niwa Y, Yamada S, Fujii T, Nakayama G, Fujiwara M, Kodera Y.

Int J Cancer. 2016 Nov 15;139(10):2290-8. doi: 10.1002/ijc.30286. Epub 2016 Aug 6.

45.

The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.

Yabusaki N, Fujii T, Yamada S, Murotani K, Sugimoto H, Kanda M, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Medicine (Baltimore). 2016 Jul;95(29):e4282. doi: 10.1097/MD.0000000000004282.

46.

Neurotrophin Receptor-Interacting Melanoma Antigen-Encoding Gene Homolog is Associated with Malignant Phenotype of Gastric Cancer.

Kanda M, Shimizu D, Fujii T, Tanaka H, Tanaka Y, Ezaka K, Shibata M, Takami H, Hashimoto R, Sueoka S, Iwata N, Kobayashi D, Tanaka C, Yamada S, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Ann Surg Oncol. 2016 Aug;23(Suppl 4):532-539. Epub 2016 Jun 30.

PMID:
27364510
47.

Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer.

Kanda M, Shimizu D, Fujii T, Tanaka H, Shibata M, Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Int J Oncol. 2016 Sep;49(3):1195-202. doi: 10.3892/ijo.2016.3584. Epub 2016 Jun 17.

PMID:
27315569
48.

Nutritional predictors for postoperative short-term and long-term outcomes of patients with gastric cancer.

Kanda M, Mizuno A, Tanaka C, Kobayashi D, Fujiwara M, Iwata N, Hayashi M, Yamada S, Nakayama G, Fujii T, Sugimoto H, Koike M, Takami H, Niwa Y, Murotani K, Kodera Y.

Medicine (Baltimore). 2016 Jun;95(24):e3781. doi: 10.1097/MD.0000000000003781. Erratum in: Medicine (Baltimore). 2016 Aug 07;95(31):e5074.

49.

Adverse impact of low skeletal muscle index on the prognosis of hepatocellular carcinoma after hepatic resection.

Yabusaki N, Fujii T, Yamada S, Suzuki K, Sugimoto H, Kanda M, Nakayama G, Koike M, Fujiwara M, Kodera Y.

Int J Surg. 2016 Jun;30:136-42. doi: 10.1016/j.ijsu.2016.04.049. Epub 2016 May 4.

50.

Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter.

Yamada S, Fujii T, Yabusaki N, Murotani K, Iwata N, Kanda M, Tanaka C, Nakayama G, Sugimoto H, Koike M, Fujiwara M, Kodera Y.

Medicine (Baltimore). 2016 May;95(18):e3582. doi: 10.1097/MD.0000000000003582.

Supplemental Content

Loading ...
Support Center